of the 2 cohorts they had a 66% CR with the IL2 additive, compared to like 33% response didnt they ?.
Also given that they have been able to recruit 40 bowel cancer pts here in Australia gives me great confidence that theres alot happening behind closed doors, and very pleased theyve shut up for a while, as the more they spoke they more the market dropped.
Fingers crossed great results from all trials, and a move into phase II in 2025
IMU Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)